- Zacks•1 hour ago
Ionis' (IONS) partner, Biogen (BIIB) has completed the rolling submission of an NDA for nusinersen for the treatment of spinal muscular atrophy.
- 24/7 Wall St.•4 hours ago
The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.
- Business Wire•yesterdayBiogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy
Biogen and Ionis today announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for the approval of nusinersen, an investigational treatment for spinal muscular atrophy .
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||312.17 x 100|
|Ask||312.43 x 100|
|Day's Range||307.50 - 313.19|
|52wk Range||223.02 - 333.65|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||18.24|
|Avg Vol (3m)||1,801,009|
|Dividend & Yield||N/A (N/A)|